Regentis Biomaterials
Update in progressRGNT (NYSE American)
- Company RatingNeutralCompany RatingCombines sentiment and sustainability signals into an overall assessment of the company.Great · Good · Neutral · At Risk · Poor
- SectorHealthcare
- IndustryMedical Instruments & Supplies
Regentis Biomaterials Ltd. is a regenerative medicine company that develops and commercializes tissue repair solutions in the United States. Its Gelrin platform uses a polyethylene glycol diacrylate hydrogel matrix with denatured fibrinogen to support tissue repair. GelrinC is a cell-free, off-the-shelf hydrogel in Phase II trials for knee cartilage injuries. The company was founded in 2004 and is based in Herzliya, Israel.
Company score
- Sentiment
- 0.55
- SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
- Environment
- 0.00
- EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
- Social
- 0.57
- Governance
- 0.00
- GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
- Sustainability
- 0.17
- SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
- Impact Score
- 0.36
- Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive
Company
- MarketNYSE American (ASE)
- LocationIsrael
- CEODr. Ehud Geller Ph.D.
- Founded2004
- Websitewww.regentis.co.il
Identifiers
- ISINIL0012190968
- CUSIP758949101
- CIK0001000693